Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue.
Parkinson's disease is a disabling neurodegenerative disorder of unknown etiology characterized by a predominant and progressive loss of dopaminergic neurons in the substantia nigra. Recent findings suggest that impaired energy metabolism plays an important role in the pathogenesis of this disorder. The endogenously occurring guanidino compound creatine is a substrate for mitochondrial and cytosolic creatine kinases. Creatine supplementation improves the function of the creatine kinase/phosphocreatine system by increasing cellular creatine and phosphocreatine levels and the rate of ATP resynthesis. In addition, mitochondrial creatine kinase together with high cytoplasmic creatine levels inhibit mitochondrial permeability transition, a major step in early apoptosis. In the present study, we analyzed the effects of externally added creatine on the survival and morphology of dopaminergic neurons and also addressed its neuroprotective properties in primary cultures of E14 rat ventral mesencephalon. Chronic administration of creatine [5 mM] for 7 days significantly increased survival (by 1.32-fold) and soma size (by 1.12-fold) of dopaminergic neurons, while having no effect on other investigated morphological parameters. Most importantly, concurrent creatine exerted significant neuroprotection for dopaminergic neurons against neurotoxic insults induced by serum and glucose deprivation (P < 0.01), 1-methyl-4-phenyl pyridinium ion (MPP+) [15 microM] and 6-hydroxydopamine (6-OHDA) [90 microM] exposure (P < 0.01). In addition, creatine treatment significantly protected dopaminergic cells facing MPP+-induced deterioration of neuronal morphology including overall process length/neuron (by 60%), number of branching points/neuron (by 80%) and area of influence per individual neuron (by 60%). Less pronounced effects on overall process length/neuron and number of branching points/neuron were also found after 6-OHDA exposure (P < 0.05) and serum/glucose deprivation (P < 0.05). In conclusion, our findings identify creatine as a rather potent natural survival- and neuroprotective factor for developing nigral dopaminergic neurons, which is of relevance for therapeutic approaches in Parkinson's disease and for the improvement of cell replacement strategies.
Andres
R H
RH
Department of Neurosurgery, University Hospital, CH-3010 Berne, Switzerland.
Huber
A W
AW
Schlattner
U
U
Pérez-Bouza
A
A
Krebs
S H
SH
Seiler
R W
RW
Wallimann
T
T
Widmer
H R
HR
D015655:1-Methyl-4-phenylpyridinium / Q000494:pharmacology; D000818:Animals; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003401:Creatine / Q000494:pharmacology*; D003402:Creatine Kinase / Q000378:metabolism; D052276:Creatine Kinase, BB Form; D052281:Creatine Kinase, Mitochondrial Form; D003404:Creatinine / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D004347:Drug Interactions; D005260:Female; D007527:Isoenzymes / Q000378:metabolism; D008636:Mesencephalon / Q000166:cytology*; D009474:Neurons / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D016627:Oxidopamine / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013565:Sympatholytics / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D007527:Isoenzymes; D013565:Sympatholytics; D016627:Oxidopamine; D003404:Creatinine; D014446:Tyrosine 3-Monooxygenase; D003402:Creatine Kinase; D052276:Creatine Kinase, BB Form; D052281:Creatine Kinase, Mitochondrial Form; D003401:Creatine; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine